Although this study primarily focused on AE reports of hyponatremia in which nivolumab, pembrolizumab, or atezolizumab were identified as the primary suspected drugs, a total of 71 concomitant medications associated with PD-1/PD-L1 inhibitors were also analyzed using the shrinkage measure method for signal detection (38, 39). The gene discussed is PDCD1; the disease is Hyponatremia.